Security
Telomir Pharmaceuticals, Inc. Common Stock · TELO
TELONASDAQCommon stockCurrentCIK 1971532Updated Oct 7, 2026
TELO price & chart
Loading TradingView…
NASDAQ:TELO on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
DEFA14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,402,117Source | 1,041,985Source | 5,365,904Source | 829,611Source | 2,101,722Source | 5,789,536Source | 491,188Source | 3,503,122Source | 7,341,361Source | 1,324,005Source | 4,773,768Source | 48,730Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 7,402,117Source | 1,041,985Source | 5,365,904Source | 829,611Source | 2,101,722Source | 5,789,536Source | 491,188Source | 3,503,122Source | 7,341,361Source | 1,324,005Source | 435,225Source | 48,730Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 422,807Source | 599,911Source | 332,424Source | 348,388Source | 534,155Source | 827,310Source | 652,294Source | 486,552Source | 1,427,991Source | 680,968Source | 1,335,564Source | 986,008Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 45,928,180Source | 28,140,559Source | 48,756,018Source | 38,327,799Source | 23,335,319Source | 46,963,236Source | 32,615,580Source | 23,335,319Source | 46,923,433Source | 31,239,895Source | 17,502,346Source | 55,000Source |
| Retained Earnings (Accumulated Deficit)USD | -38,948,870Source | -27,698,485Source | -43,722,538Source | -37,846,576Source | -21,767,752Source | -42,001,010Source | -32,776,686Source | -20,318,749Source | -41,010,063Source | -30,596,858Source | -14,064,142Source | -992,278Source |
| Stockholders' Equity Attributable to ParentUSD | 6,979,310Source | 442,074Source | 5,033,480Source | 481,223Source | 1,567,567Source | 4,962,226Source | -161,105Source | 3,016,570Source | 5,913,370Source | 643,037Source | 3,438,204Source | -937,278Source |
| Liabilities and EquityUSD | 7,402,117Source | 1,041,985Source | 5,365,904Source | 829,611Source | 2,101,722Source | 5,789,536Source | 491,188Source | 3,503,122Source | 7,341,361Source | 1,324,005Source | 4,773,768Source | 48,730Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 422,807Source | 599,911Source | 332,424Source | 348,388Source | 534,155Source | 827,310Source | 652,294Source | 486,552Source | 1,427,991Source | 680,968Source | 1,335,564Source | 986,008Source |
| Cash and Cash Equivalents, at Carrying Value | — | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 39,803Source | 1,375,686Source | 5,290,329Source | 6,867,276Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,773,510Source | -863,132Source | -3,688,188Source | -5,070,428Source | -3,859,796Source | -468,661Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 47,351Source | — | 9,708,727Source | 6,335,328Source | 3,859,608Source | 470,080Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,726,159Source | -863,132Source | 6,020,539Source | 1,264,900Source | -188Source | 1,419Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 198,734Source | 4,664,450Source | 39,803,000,000Source | 1,375,686,000,000Source | 5,300,000Source | 6,900,000Source | — | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | 4,338,543Source | 1,611,458Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | -7,486,767Source | — |
| General and Administrative ExpenseUSD | — | — | 386,951Source | 5,378,744Source | 1,320,002Source | 5,027,071Source | 573,539Source | 1,850,786Source | 8,103,280Source | 9,636,333Source | 600,192Source | 20,941Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | 3,028Source | 1,342Source | 1,255Source | 46Source | — | 4,338,542Source | — | — |
| Investment Income, InterestUSD | — | — | 44,182Source | 15,445Source | 46,176Source | 1,362Source | 51,644Source | 8,000Source | 125,644Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,102,294Source | -5,990,733Source | -1,721,528Source | -5,069,890Source | -990,947Source | -2,179,828Source | -10,413,205Source | -16,532,716Source | -13,071,864Source | -854,147Source |
| Operating ExpensesUSD | — | — | 1,146,476Source | 6,006,178Source | 1,764,676Source | 5,069,910Source | 1,041,336Source | 2,187,782Source | 10,538,849Source | 12,242,174Source | 3,942,048Source | 854,147Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 255,970Source | 47,311Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 6,832,973Source | 1,000,000Source | — |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,102,294Source | -5,990,733Source | -1,721,528Source | -5,069,890Source | -990,947Source | -2,179,828Source | -10,413,205Source | -16,532,716Source | -13,071,864Source | -854,147Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.03Source | -0.2Source | -0.79Source | -0.17Source | -0.03Source | -0.07Source | -0.33Source | 0.56Source | -0.48Source | -0.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.03Source | -0.2Source | -0.79Source | -0.17Source | -0.03Source | -0.07Source | -0.33Source | 0.56Source | -0.45Source | -0.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 32,398,906Source | 29,609,814Source | 60,837,460Source | 30,010,165Source | 34,380,971Source | 29,762,671Source | 31,653,094Source | 29,539,219Source | 27,304,724Source | 26,829,284Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 32,398,906Source | 29,609,814Source | 60,837,460Source | 30,010,165Source | 34,380,971Source | 29,762,671Source | 31,653,094Source | 29,539,219Source | 29,017,857Source | 26,829,284Source |
| Interest Expense (non-operating)USD | — | — | — | — | 3,028Source | 1,342Source | 1,255Source | 46Source | — | 4,338,542Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 386,951Source | 5,378,744Source | 1,320,002Source | 5,027,071Source | 573,539Source | 1,850,786Source | 8,103,280Source | 9,636,333Source | 600,192Source | 20,941Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,643,049Source | — |
| Interest Income, OtherUSD | — | — | — | 15,445Source | — | — | — | — | — | 48,000Source | — | — |
| Investment Income, InterestUSD | — | — | 44,182Source | 15,445Source | 46,176Source | 1,362Source | 51,644Source | 8,000Source | 125,644Source | — | — | — |
| Operating ExpensesUSD | — | — | 1,146,476Source | 6,006,178Source | 1,764,676Source | 5,069,910Source | 1,041,336Source | 2,187,782Source | 10,538,849Source | 12,242,174Source | 3,942,048Source | 854,147Source |
| Research and Development ExpenseUSD | — | — | 759,525Source | 627,434Source | 444,674Source | 42,839Source | 467,797Source | 336,996Source | 2,435,569Source | 2,235,341Source | 1,574,306Source | 833,206Source |
| Operating Income (Loss) | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Preferred Stock Dividends, Income Statement Impact | — | — | — | — | —Source | — | — | — | — | — | — | — |
Filing attachments
ex4-1.htm · 8-K · 2026-10-06
Exhibit 4.1 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMP…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC) MIAMI, Oct. 6, 2026 (GLOBE NEWSWIRE) - Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targetin…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology MIAMI, September 17, 2026 (GLOBE NEWSWIRE) - Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-mo…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site Initiation MIAMI, Sept. 14 (GLOBE NEWSWIRE) - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic a…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models. MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutic…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn’s Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS News…
Read attachment ↗